MPX Bioceutical Corporation reported consolidated earnings results for the first quarter Ended June 30, 2018. For the quarter, the company reported revenue of CAD 14,464,989 as compared to CAD 4,465,438 a year ago. Adjusted LBITDA was CAD 1,802,463 as compared EBITDA of CAD 102,324 a year ago. This was the result of costs incurred related to continued capacity expansion, increased staffing and planning for new operations and expenses associated with the Company’s continued growth initiatives. Loss from operations was CAD 5,140,237 against CAD 477,102 a year ago. Net loss was CAD 12,087,512 or CAD 0.03 per share basic and diluted against CAD 790,575 or CAD 0.01 per share basic and diluted a year ago. Revenue was generated primarily by the MPX’s Arizona management operations, including sales from the four Arizona dispensaries, including a full quarter of sales from the Company’s recent acquisition in the state. Revenue was additionally generated by wholesale sales of MPX branded concentrates to licensed dispensaries operating within Arizona.